Doctor Erik Michaelsson
Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg (Sweden)
Myeloperoxidase inhibition reverses the inflammatory proteomic pattern in heart failure with preserved ejection fraction
Event: Heart Failure 2021
Topic: Pharmacotherapy
Session: Chronic Heart Failure - Treatment 2
ESC 365 is supported by
